Published by Josh White on 17th February 2025
(Sharecast News) - IP Group said on Monday that its portfolio company Istesso has reported results from a phase 2b study of its investigational rheumatoid arthritis (RA) drug, leramistat, which did not meet its primary endpoint of improved ACR20 response versus placebo.
URL: http://www.digitallook.com/dl/news/story/34884792/...